Evidence map›Paper›PMID 40199931›Full record

ArticleScientific reports2025

An open source, PCR based, point-of-care testing platform.

Yaping Xie, Zhou Sha, Shuaiwu Huang, Chiwei Yin, Liangcheng Wan, Jianjun Li, Jiangang Ling, Chang Wu, Lizhong Dai

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Comprehensive Review on Viral RNA Extraction Strategies for Enhanced Molecular Diagnostics.Interdisciplinary perspectives on infectious diseases · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaping XieResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Zhou ShaResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Shuaiwu HuangResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Chiwei YinResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Liangcheng WanResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Jianjun LiResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Jiangang LingResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Chang WuResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China.
Lizhong DaiResearch and Development Department, Sansure Biotech Co., Ltd, Changsha, 410125, China. lizhongdai@sansure.com.cn.

Funding

Central Guidance Local Special Funds 2024ZYC031Joint Funds of the National Natural Science Foundation of China 2024JJ9151
6 · The paper itself

Abstract

In recent years, point-of-care nucleic acid testing had played an important role in the diagnosis of infectious diseases. Despite its advantages, current point-of-care testing (POCT) platforms were all closed, which hindered researchers from quickly validating the performance of customized reagents. Incompatibility and repeated development of different POCT devices also resulted in the waste of medical resources. In this article, a rotating cartridge with a detachable reagent rack was developed, which provided an open platform in conjunction with a programmable POCT instrument. The system had been confirmed to effectively detect the HPV sample with a concentration of 1000 copies per milliliter and the novel coronavirus nucleic acid control dilution with a concentration of 200 copies per milliliter within 1 h. The cartridge could detect six targets simultaneously and cost less than ten dollars. The square of the correlation coefficients of the fitting line between the dye concentration and the fluorescence intensity all exceeded 0.99. The coefficient of variation (CV) for testing one sample with multiple cartridges or instruments was under 3%, confirming the stability and reliability of system performance. Results of clinical testing further verified its ability to detect multiple viruses, including novel coronavirus, influenza and human papillomavirus. Compared with standard results, the sensitivity reached 100% in the detection of multiple respiratory viruses and HPV viruses while the specificity was above 98% for all targets. The area under the curve (AUC) values for all receiver operating characteristic (ROC) curves exceeded 0.98. These results indicated that this platform had excellent performances and provided a competitive solution for low-cost, open point-of-care nucleic acid testing.

Indexed as

Point-of-Care TestingPolymerase Chain ReactionCOVID-19HumansPapillomaviridaePapillomavirus InfectionsReproducibility of ResultsSARS-CoV-2Sensitivity and SpecificityCartridgeDetachableInfectious diseaseNucleic acidPoint-of-care

Identifiers

PMID40199931
PMCPMC11978785

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.